Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS/MS

Thompson, A., Schäfer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G., Neumann, T., & Hamon, C. (2003) · Analytical Chemistry · doi:10.1021/ac0262560 · Cited by 2,425

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

Ebert, B. L., Pretz, J. L., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E. C., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 953

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome

Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509

Targeted protein degradation: from mechanisms to clinic

Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Qi, S., Dong, J., Xu, Z., Cheng, X., Zhang, W., & Qin, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 306

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

Guo, W., Qi, X., Yu, X., Liu, Y., Chung, C.-I., Bai, F., Lin, X., Lu, D., Wang, L., Chen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17997-6 · Cited by 228

Immunotherapy of multiple myeloma

Minnie, S. A., & Hill, G. R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129205 · Cited by 222

Targeted protein degradation as a powerful research tool in basic biology and drug target discovery

Wu, T., Yoon, H., Xiong, Y., Dixon-Clarke, S. E., Nowak, R. P., & Fischer, E. S. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0438-0 · Cited by 186

Harnessing the Power of Proteolysis for Targeted Protein Inactivation

Verma, R., Mohl, D., & Deshaies, R. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.010 · Cited by 185

EP300 Selectively Controls the Enhancer Landscape of MYCN -Amplified Neuroblastoma

Durbin, A. D., Wang, T., Wimalasena, V. K., Zimmerman, M. W., Li, D., Dharia, N. V., Mariani, L., Shendy, N. A. M., Nance, S., Patel, A. G., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0385 · Cited by 181

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma

Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 184

Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

Yamamoto, J., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00116k · Cited by 169

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Barrios, V. A. Q., et al. (2022) · Blood · doi:10.1182/blood.2021014956 · Cited by 156

Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD

Blazar, B. R., Hill, G. R., & Murphy, W. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0356-4 · Cited by 148

Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders

Hanzl, A., Casement, R., Imrichova, H., Hughes, S. J., Barone, E., Testa, A., Bauer, S., Wright, J., Brand, M., Ciulli, A., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01177-2 · Cited by 133

Acute pharmacological degradation of Helios destabilizes regulatory T cells

Wang, E. S., Verano, A. L., Nowak, R. P., Yuan, J. C., Donovan, K. A., Eleuteri, N. A., Yue, H., Ngo, K. H., Lizotte, P. H., Gokhale, P. C., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00802-w · Cited by 124

Molecular mechanisms of thalidomide and its derivatives

Ito, T., & Handa, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.016 · Cited by 123

Rapid and deep-scale ubiquitylation profiling for biology and translational research

Udeshi, N. D., Mani, D. R., Satpathy, S., Fereshetian, S., Gasser, J. A., Svinkina, T., Olive, M. E., Ebert, B. L., Mertins, P., & Carr, S. A. (2020) · Nature Communications · doi:10.1038/s41467-019-14175-1 · Cited by 110

Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy

Meermeier, E. W., Welsh, S. J., Sharik, M. E., Du, M. T., Garbitt, V. M., Riggs, D. L., Shi, C., Stein, C. K., Bergsagel, M., Chau, B. H., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0038 · Cited by 116

Cereblon modulators: Low molecular weight inducers of protein degradation

Chamberlain, P. P., & Cathers, B. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.004 · Cited by 106

Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma

Detappe, A., Nguyen, H. V. ‐., Jiang, Y., Agius, M. P., Wang, W., Mathieu, C., Su, N. K., Kristufek, S. L., Lundberg, D. J., Bhagchandani, S. H., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-022-01310-1 · Cited by 107

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Larráyoz, M., Garcia-Barchino, M. J., Celay, J., Etxebeste, A., Jiménez, M., Pérez, C., Ordóñez, R., Cobaleda, C., Botta, C., Fresquet, V., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02178-3 · Cited by 93

Thalidomide and its metabolite 5‐hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF

Yamanaka, S., Murai, H., Saito, D., Abe, G., Tokunaga, E., Iwasaki, T., Takahashi, H., Takeda, H., Suzuki, T., Shibata, N., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105375 · Cited by 89

Molecular Mechanisms of the Teratogenic Effects of Thalidomide

Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2020) · Pharmaceuticals · doi:10.3390/ph13050095 · Cited by 88

Continuous evolution of compact protein degradation tags regulated by selective molecular glues

Mercer, J. A. M., DeCarlo, S. J., Burman, S. S. R., Sreekanth, V., Nelson, A. T., Hunkeler, M., Chen, P. J., Donovan, K. A., Kokkonda, P., Tiwari, P. K., et al. (2024) · Science · doi:10.1126/science.adk4422 · Cited by 85

Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs

Gemechu, Y., Millrine, D., Hashimoto, S., Prakash, J., Sanchenkova, K., Metwally, H., Parajuli, G., Kang, S., & Kishimoto, T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814446115 · Cited by 78

Recent advances in the molecular mechanism of thalidomide teratogenicity

Gao, S., Wang, S., Fan, R., & Hu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110114 · Cited by 78

Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells

Sellar, R. S., Sperling, A. S., Slabicki, M. M., Gasser, J. A., McConkey, M. E., Donovan, K. A., Mageed, N., Adams, D. N., Zou, C., Miller, P. G., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153514 · Cited by 76

Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality

Chamberlain, P. P., D’Agostino, L. A., Ellis, J. M., Hansen, J. D., Matyskiela, M. E., McDonald, J. J., Riggs, J. R., & Hamann, L. G. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00425 · Cited by 69

Induced protein degradation for therapeutics: past, present, and future

Yoon, H., Rutter, J. C., Li, Y.-D., & Ebert, B. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175265 · Cited by 72

Peptidic degron for IMiD-induced degradation of heterologous proteins

Koduri, V., McBrayer, S. K., Liberzon, E., Wang, A. C., Briggs, K. J., Cho, H., & Kaelin, W. G. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818109116 · Cited by 64

Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology

Ito, T., Yamaguchi, Y., & Handa, H. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.012 · Cited by 60

Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity

Hahn, F., Hamilton, S. T., Wangen, C., Wild, M. R., Kicuntod, J., Brückner, N., Follett, J. E. L., Herrmann, L., Kheimar, A., Kaufer, B. B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312858 · Cited by 64

An industry perspective on the FDA modernization act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development

Carratt, S. A., Zuch de Zafra, C. L., Oziolor, E., Rana, P., Vansell, N. R., Mangipudy, R., & Vaidya, V. S. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfae122 · Cited by 59

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia

Aubrey, B. J., Cutler, J. A., Bourgeois, W., Donovan, K. A., Gu, S. S., Hatton, C., Perlee, S. C., Perner, F., Rahnamoun, H., Theall, A. C. P., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00366-1 · Cited by 58

Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells

Park, S.-M., Miyamoto, D. K., Han, G. Y. Q., Chan, M., Curnutt, N. M., Tran, N. L., Velleca, A., Kim, J. H., Schurer, A., Chang, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.010 · Cited by 56

SLC44A2 regulates vascular smooth muscle cell phenotypic switching and aortic aneurysm

Song, T., Zhao, S., Luo, S., Chen, C., Liu, X., Wu, X., Sun, Z., Cao, J., Wang, Z., Wang, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173690 · Cited by 57

The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages

Mougiakakos, D., Bach, C., Böttcher, M., Beier, F., Röhner, L., Stoll, A., Rehli, M., Gebhard, C., Lischer, C., Eberhardt, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0555 · Cited by 51

Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions

Gao, Y., Jiang, B., Kim, H., Berberich, M. J., Che, J., Donovan, K. A., Hatcher, J. M., Huerta, F., Kwiatkowski, N. P., Liu, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01864 · Cited by 51

Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies

Renneville, A., Gasser, J. A., Grinshpun, D. E., Beltran, P. M. J., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M. E., Viswanathan, K., Tepper, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0105 · Cited by 46

Mechanisms of lenalidomide sensitivity and resistance

Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 48

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome

Martinez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Mo, A., Docking, T. R., Gharaee, N., Li, J., Umlandt, P., Fuller, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0497-9 · Cited by 42

The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia

Chang, Y., Keramatnia, F., Ghate, P. S., Nishiguchi, G., Gao, Q., Iacobucci, I., Yang, L., Chepyala, D., Mishra, A., High, A. A., et al. (2023) · Blood · doi:10.1182/blood.2022017813 · Cited by 40

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40

Identification and characterization of cancer vulnerabilities via targeted protein degradation

Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML

Bourgeois, W., Cutler, J. A., Aubrey, B. J., Wenge, D. V., Perner, F., Martucci, C., Henrich, J. A., Klega, K. S., Nowak, R. P., Donovan, K. A., et al. (2023) · Blood · doi:10.1182/blood.2023021105 · Cited by 32

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer

He, T., Cheng, C., Qiao, Y., Cho, H., YOUNG, E. A., Mannan, R., Mahapatra, S., Miner, S. J., Zheng, Y., Kim, N. H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322563121 · Cited by 30

Phenotypic screening with target identification and validation in the discovery and development of E3 ligase modulators

Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 31

Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs

Beedie, S., Huang, P. A., Harris, E. M., Strope, J. D., Mahony, C. B., Chau, C. H., Vargesson, N., & Figg, W. D. (2020) · The FASEB Journal · doi:10.1096/fj.201903060rr · Cited by 28

Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy

Chen, Z., Dhruv, H., Zhang, X., Rej, R. K., Bai, L., McEachern, D., Kirchhoff, P. D., Nagilla, R., Jolivette, L. J., Rice, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58431-z · Cited by 28

Discovering new biology with drug-resistance alleles

Freedy, A. M., & Liau, B. B. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00865-9 · Cited by 25

Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation

Li, P., Hu, X., Fan, Z., Sun, S., Ran, Q., Wei, T., Wei, P., Jiang, Q., Yan, J. W., Yang, N., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01592-z · Cited by 26

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

Minnie, S. A., Waltner, O. G., Ensbey, K. S., Olver, S. D., Collinge, A. D., Sester, D. P., Schmidt, C. R., Legg, S. R. W., Takahashi, S., Nemychenkov, N. S., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157907 · Cited by 22

Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy

Colley, A., Brauns, T. A., Sluder, A. E., Poznansky, M. C., & Gemechu, Y. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.001 · Cited by 20

Development of an AchillesTAG degradation system and its application to control CAR-T activity

Veits, G. K., Henderson, C. S., Vogelaar, A. L., Eron, S. J., Lee, L., Hart, A. A., Deibler, R. W., Baddour, J., Elam, W. A., Agafonov, R. V., et al. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100010 · Cited by 22

Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling

Geng, C., Chen, J., Song, T., Jung, J. H., Long, M., Song, M., Ji, T., Min, B. S., Lee, J. G., Peng, B., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.012 · Cited by 23

Mechano-oncogenic cytoskeletal remodeling drives leukemic transformation with mitochondrial vesicle-mediated STING activation

Song, Z., Cui, Y., Xin, L., Xiao, R., Feng, J., Li, C., Yin, Z., Wang, H., Li, Q., Wang, M., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.01.013 · Cited by 22

Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents

Nutt, M. J., & Stewart, S. G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104010 · Cited by 20

Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury

Lecca, D., Hsueh, S., Luo, W., Tweedie, D., Kim, D. S., Baig, A. M., Vargesson, N., Kim, Y. K., Hwang, I., Kim, S., et al. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00907-5 · Cited by 17

The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases

Zhou, L., & Xu, G. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167457 · Cited by 17

The emerging role of targeted protein degradation to treat and study cancer

Brodermann, M. H., Henderson, E. K., & Sellar, R. S. (2024) · The Journal of Pathology · doi:10.1002/path.6301 · Cited by 15

The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance

Zou, J., Jones, R. J., Wang, H., Kuiatse, I., Shirazi, F., Manasanch, E. E., Lee, H. C., Sullivan, R., Fung, L. M., Richard, N., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01943-6 · Cited by 14

Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model

Flietner, E., Wen, Z. H., Rajagopalan, A., Jung, O., Watkins, L. R., Wiesner, J., You, X., Zhou, Y., Sun, Y., Kingstad-Bakke, B. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-14114-z · Cited by 13

Precision preclinical modeling to advance cancer treatment

Gutmann, D. H., Boehm, J. S., Karlsson, E. K., Padron, E., Seshadri, M., WALLIS, D. E., & Snyder, J. C. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae249 · Cited by 14

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells

Bouguenina, H., Nicolaou, S., Bihan, Y. L., Bowling, E. A., Calderon, C., Caldwell, J., Harrington, B., Hayes, A., McAndrew, C., Mitsopoulos, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107059 · Cited by 12

Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer

Lu, X., Wang, X., Yang, Z., Wang, X., Wang, L., Xu, C., Lo, I., Geng, C., Wang, L., Pu, Y., et al. (2026) · Nature · doi:10.1038/s41586-026-10613-5 · Cited by 15

A Molecular Glue Approach to Control the Half-Life of CRISPR-Based Technologies

Sreekanth, V., Jan, M., Zhao, K. T., Lim, D., Siriwongsup, S., Davis, J. R., McConkey, M. E., Kovalcik, V., Barkal, S., Law, B. K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06230 · Cited by 12

Thalidomide-induced limb malformations: an update and reevaluation

Collins, M. D., & Scott, W. J. (2025) · Archives of Toxicology · doi:10.1007/s00204-024-03930-z · Cited by 10

Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors

Kotagiri, S., Wang, Y., Han, Y., Liang, X., Blazanin, N., Mazhar, H., Sebastian, M. M., Nguyen, P. K., Jiang, Y., & Lissanu, Y. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02577 · Cited by 9

ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC

Tran, N. L., Jiang, J., Ma, M., Gadbois, G. E., Gulay, K. C. M., Verano, A. L., Schiavon, C. R., Rebollo, E., Zhou, H., Huang, C., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01978-1 · Cited by 14

Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens

Falvo, P., Orecchioni, S., Roma, S., Raveane, A., & Bertolini, F. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200817104912 · Cited by 9

Discovery of a Novel Series of iso -Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue Degraders

Zhang, X., Dhruv, H., Deng, Q., Tudor, M., Bechtel, N., Nagilla, R., Jolivette, L. J., Rice, C., Orth, P., Behshad, E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00668 · Cited by 9

Drugging the undruggable: Chemical and biological insights into molecular glues in the pipeline

Metwally, K. A., Yahya, G., & Abo-Dya, N. E. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118132 · Cited by 9

Cancer Biology of GSPT1: Mechanisms and Targeted Therapy Opportunities of Molecular Glue Degraders

Lin, Q., Liu, W., Lu, W., Zhao, M., Cao, L., Li, Z., Wang, J., Xu, X. J., & Wu, H. (2025) · Advanced Science · doi:10.1002/advs.202511789 · Cited by 8

Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury

Hsueh, S., Scerba, M. T., Tweedie, D., Lecca, D., Kim, D. S., Baig, A. M., Kim, Y. K., Hwang, I., Kim, S., Selman, W. R., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102449 · Cited by 8

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

Huang, P. A., Beedie, S., Chau, C. H., Venzon, D. J., Gere, S., Kazandjian, D. G., Korde, N., Mailankody, S., Landgren, O., & Figg, W. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-51446-9 · Cited by 7

Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider

Loberg, L. I., Proctor, W. R., Burdick, A. D., Cauvin, A. J., DeLise, A. M., Hemkens, M. D., Hohlbaum, A. M., Hukkanen, R. R., Sedgwick, A., Shuey, D. L., et al. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105793 · Cited by 7

Casein kinase 1α essentially regulates thrombopoiesis by driving megakaryocyte maturation and cytoskeleton organization

Kollotzek, F., Mott, K., Fischer, M., Fındık, B., Göb, V., Manke, M.-C., Borst, C. E., Polzin, A., Burkhalter, M. D., Eckly, A. E., et al. (2025) · Blood · doi:10.1182/blood.2025028460 · Cited by 7

PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives

Vorderbruggen, M., Velázquez‐Martínez, C. A., Natarajan, A., & Karpf, A. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105067 · Cited by 8

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response

Cenzano, I., Cócera, M., Larráyoz, M., Campos‐Dopazo, L., Sanz, S., Bantan, A., Vilas‐Zornoza, A., Martín‐Úriz, P. S., Aguirre‐Ruiz, P., Alignani, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74389-y · Cited by 7

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies

Chen, L., Aleman, A., Larráyoz, M., Chiu, H., Zhao, J., Oekelen, O. V., Kelly, G., Kim‐Schulze, S., Laganà, A., Jagannath, S., et al. (2026) · Blood · doi:10.1182/blood.2025030891 · Cited by 7

Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma

Louvet, C., Nadeem, O., & Smith, E. L. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0073 · Cited by 6

Drug Repurposing in Veterinary Oncology: Myth or Reality?

Ciccarelli, S., Perrone, C., Cavalera, M. A., & Giuliano, A. (2025) · Veterinary Sciences · doi:10.3390/vetsci12111067 · Cited by 5

Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn

Röhner, L., Ng, Y. L. D., Scheffold, A., Lindner, S., Köpff, S., Brandl, A., Beilhack, A., & Krönke, J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.004 · Cited by 5

Comparative Genomics Identifies Putative Interspecies Mechanisms Underlying Crbn-Sall4-Linked Thalidomide Embryopathy

Kowalski, T. W., Caldas-Garcia, G. B., Gomes, J. D. A., Fraga, L. R., Schüler‐Faccini, L., Recamonde‐Mendoza, M., Paixão‐Côrtes, V. R., & Vianna, F. S. L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.680217 · Cited by 6

In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties

Nutt, M. J., Yee, Y. S., Buyan, A., Andrewartha, N., Corry, B., Yeoh, G. C., & Stewart, S. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113353 · Cited by 4

Safety considerations for cereblon-recruiting targeted protein degraders

Garside, H., Aslamkhan, A. G., Daniels, D. L., Datta, K., Pedersen, M. E., Hukkanen, R. R., Jones, L. H., Ketter, N., Lahoti, T. S., Loberg, L. I., et al. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01426-2 · Cited by 6

Decreased RNA ‐binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide

Lin, Z., Zhang, Y., Liu, X., Luo, H., Li, Q., Gao, Q., Wang, X., Wen, J., Li, L., Yu, F., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19468 · Cited by 3

Repurposing the repurposed: thalidomide analogs as immune stimulants to overcome T cell exhaustion

Slabicki, M. M., & Sperling, A. S. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.07.004 · Cited by 3

ZBTB11 Depletion Targets Metabolic Vulnerabilities in K-Ras Inhibitor Resistant PDACPreprint

Tran, N. L., Jiang, J., Ma, M., Gadbois, G. E., Gulay, K. C. M., Verano, A. L., Zhou, H., Huang, C., Scott, D. A., Bang, A. G., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.19.594824 · Cited by 3

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C InhibitorsPreprint

Kotagiri, S., Wang, Y., Han, Y., Liang, X., Blazanin, N., Nguyen, P. K., Jiang, Y., & Lissanu, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.23.608456 · Cited by 3

Optimised genome editing for precise DNA insertion and substitution using prime editors in zebrafishPreprint

Ono, Y., Peterka, M., Love, M. I., Khan, A., Bowers, F., Bhandari, A., Gordon, E., Ball, J. S., Hammond, C., Tyler, C. R., et al. (2025) · eLife · doi:10.7554/elife.107475 · Cited by 3

Session 5: Protein Degraders

Palyada, K., Hukkanen, R. R., Leuenroth-Quinn, S., Vitsky, A., Peterson, R. E., Stamp, K., Hoover, C., & Volak, L. P. (2024) · Toxicologic Pathology · doi:10.1177/01926233241300452 · Cited by 2

Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma

Bjorklund, C. C., Larráyoz, M., Kang, J., Chiu, H., Shtraizent, N., Wu, L., Li, S., Hsu, C.-C., Zhao, J., Amatangelo, M. D., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100179 · Cited by 3

Discovery of Highly Potent and Selective IKZF2 Degraders for Cancer Immunotherapy

Wang, Y., Qi, Z., Sun, S., Wei, T., Wei, P., Jia, C., Cai, X., Zhao, Z., Qiao, M., Zou, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00500 · Cited by 2

Cereblon mediates macrophage differentiation and microglial phagocytosis by regulating calpain protease activity

Zhou, L., Sun, Q. P., & Cao, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117606 · Cited by 2

Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm

Gharaee, N., Wegrzyn-Woltosz, J., Jiang, J., Akhade, V. S., Bridgers, J., Stubbins, R. J., Hiwase, D., Kutyna, M., Chan, O., Komrokji, R. S., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02537-2 · Cited by 2

Thalidomide – From a Banned Drug to Molecular Glues, PROTACs, and New Concepts in Drug Discovery

Yamamoto, J., Handa, H., & Yamaguchi, Y. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch24 · Cited by 2

Optimised genome editing for precise DNA insertion and substitution using Prime Editors in zebrafishPreprint

Ono, Y., Peterka, M., Love, M. I., Bhandari, A., Gordon, E., Ball, J. S., Tyler, C. R., Rees, S., Bohlooly‐Y, M., Maresca, M., et al. (2025) · eLife · doi:10.7554/elife.107475.1 · Cited by 2

Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradationPreprint

Ehinger, E., Perez, K. C., Sanchez, E., Reveles, B. V., Dash, B., Arteaga-Vazquez, L. J., Johnson, E., Rao, A., & Hogan, P. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.701413 · Cited by 2

Optimised genome editing for precise DNA insertion and substitution using prime editors in zebrafish

Ono, Y., Peterka, M., Love, M. I., Khan, A., Bowers, F., Bhandari, A., Gordon, E., Ball, J. S., Hammond, C. L., Tyler, C. R., et al. (2026) · eLife · doi:10.7554/elife.107475.3 · Cited by 1

Drug discovery technologies–Current and future trends

Noe, M. C., Steppan, C. M., & Weston, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00019-4 · Cited by 1

Investigating the Mechanism and Species-Specificity of Thalidomide Derivatives

Fink, E. C. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

Investigating the Molecular Mechanisms of Action of Lenalidomide and Other Immunomodulatory Derivatives

Haldar, S. D. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn

Röhner, L., Ng, Y. L. D., Scheffold, A., Lindner, S., Köpff, S., Brandl, A., Beilhack, A., & Krönke, J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.004 · Cited by 5

Another action of a thalidomide derivative

Ito, T., & Handa, H. (2015) · Nature · doi:10.1038/nature14628 · Cited by 15

Lenalidomide induces degradation of

Hurst, S. N., & Ebert, B. L. (2016)